Related Experiment Video
Updated: May 11, 2026
11:46
Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
Published on: April 27, 2014
Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C.
Marianne Gamper1, Volker Viereck, Jakob Eberhard
1IKBT, Institut für Klinische Biomedizinische Forschung Thurgau, Lauchefeld 31, 9548, Matzingen, Switzerland, marianne.gamper@stgag.ch.
International Urogynecology Journal
|May 15, 2013
Summary
Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) ESSIC type 3C shows a local immune response with high urinary antibodies. Urinary immunoglobulin levels may aid in non-invasive diagnosis of this BPS/IC subtype.
Area of Science:
- Urology
- Immunology
- Genetics
Background:
- Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC) presents heterogeneously.
- The ESSIC type 3C subtype, identified by Hunner's lesions, exhibits distinct immune and urothelial characteristics.
- Previous gene expression studies highlighted immune responses in BPS/IC.
Purpose of the Study:
- To further characterize the BPS/IC ESSIC type 3C subtype using a gene expression panel.
- To investigate B-cell activation and urinary antibody concentrations in BPS/IC ESSIC type 3C patients.
- To identify potential non-invasive diagnostic markers for BPS/IC ESSIC type 3C.
Main Methods:
- Collected bladder biopsies, urine, and blood from 15 BPS/IC ESSIC type 3C patients, 11 overactive bladder (OAB) patients, and 8 healthy controls.
- Quantified gene expression via RT-qPCR and performed immunohistochemistry on bladder tissue.
- Measured urinary immunoglobulins G and A using ELISA and analyzed data with Kruskal-Wallis and post hoc tests.
Main Results:
- BPS/IC ESSIC type 3C patients exclusively showed high expression of T- and B-cell markers (e.g., CD20, CD79A) and low expression of urothelial markers (e.g., KRT20, UPK1B).
- Focal lymphoid aggregates were observed in the submucosa of BPS/IC ESSIC type 3C bladders.
- Elevated urinary immunoglobulin concentrations were found solely in BPS/IC ESSIC type 3C patients.
Conclusions:
- BPS/IC ESSIC type 3C is characterized by a localized adaptive immune response.
- Elevated urinary antibody concentrations are a key feature of this BPS/IC subtype.
- Urinary immunoglobulin quantification offers a potential non-invasive diagnostic method for BPS/IC ESSIC type 3C.
Related Concept Videos
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
01:23Irritable Bowel Syndrome
DefinitionIrritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent combinations of abdominal pain, bloating, diarrhea, or constipation.Pathophysiology of irritable bowel syndromeIts pathophysiology is multifactorial, involving disturbances in motility, sensory processing, microbial balance, barrier integrity, and gut–brain communication. These mechanisms interact to produce symptoms that vary across IBS subtypes.Altered Motility PatternsDisordered...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:17Irritable Bowel Syndrome I: Introduction
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are: